Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
7/17/25 | GSK (GSK) | Blenrep for Multiple Myeloma (MM) | Subscribers Only | Subscribers Only | Subscribers Only |
7/16/25 | Fortress Biotech (FBIO) | CAEL-101 for Amyloid light-chain (AL) Amyloidosis | Subscribers Only | Subscribers Only | Subscribers Only |
7/16/25 | Merck & Co (MRK) | MK-8527 for HIV / AIDS Treatment | Subscribers Only | Subscribers Only | Subscribers Only |
7/15/25 | Merck & Co (MRK) | MK-8591B for HIV / AIDS Treatment | Subscribers Only | Subscribers Only | Subscribers Only |
7/15/25 | Merck & Co (MRK) | MK-8507 for HIV / AIDS Treatment | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
04/01/2025 | Subscribers Only | Subscribers Only | Company - Divestment/Spinoff |
04/24/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
05/20/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
05/22/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
06/02/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |